| RYAPX | RYARX | RYAPX / RYARX | |
| Total Expense Ratio | 1.68 | 1.70 | 99% |
| Annual Report Gross Expense Ratio | 1.79 | 1.83 | 98% |
| Fund Existence | 22 years | 22 years | - |
| Gain YTD | -9.917 | -6.827 | 145% |
| Front Load | 5% | 5% | 100% |
| Min. Initial Investment | 2500 | 2500 | 100% |
| Min. Initial Investment IRA | 1000 | 1000 | 100% |
| Net Assets | 76.9M | 32M | 240% |
| Annual Yield % from dividends | 2.61 | 4.59 | 57% |
| Returns for 1 year | -15.82 | -11.97 | 132% |
| Returns for 3 years | -44.60 | -35.15 | 127% |
| Returns for 5 years | -51.95 | -40.51 | 128% |
| Returns for 10 years | -88.11 | -76.89 | 115% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BST | 46.26 | 0.59 | +1.29% |
| BlackRock Science and Technology Trust | |||
| JULB | 27.67 | 0.15 | +0.54% |
| Aptus July Buffer ETF | |||
| DYLD | 22.26 | N/A | -0.02% |
| LeaderShares® Dynamic Yield ETF | |||
| FDEV | 37.15 | -0.31 | -0.83% |
| Fidelity International Multifactor ETF | |||
| THNR | 25.40 | -0.47 | -1.81% |
| Amplify Weight Loss Drug & Treatment ETF | |||